Skip to main content
Premium Trial:

Request an Annual Quote

CombiMatrix to Invest $4M in Cancer Drug Company Leuchemix

NEW YORK, Oct. 4 (GenomeWeb News) - CombiMatrix will take a 33 percent stake in cancer drug discovery firm Leuchemix, it parent company Acacia Research said today.


In exchange for equity ownership in the form of preferred stock, CombiMatrix will pay Leuchemix a total of $4 million in quarterly installments over the next two years.


Leuchemix is developing a series of small molecules that have shown efficacy against various leukemias and solid tumors in animal models. The company plans to file its first investigational new drug application in 2005.

The Scan

Study Links Genetic Risk for ADHD With Alzheimer's Disease

A higher polygenic risk score for attention-deficit/hyperactivity disorder is also linked to cognitive decline and Alzheimer's disease, a new study in Molecular Psychiatry finds.

Study Offers Insights Into Role of Structural Variants in Cancer

A new study in Nature using cell lines shows that structural variants can enable oncogene activation.

Computer Model Uses Genetics, Health Data to Predict Mental Disorders

A new model in JAMA Psychiatry finds combining genetic and health record data can predict a mental disorder diagnosis before one is made clinically.

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.